Radiosynthesis and validation of [5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl) furan-2-carboxamide] ([11C]CPPC), a PET radiotracer for imaging CSF1R, a microglia-specific marker

Research output: Contribution to journalArticle

Abstract

In this practitioner protocol, the radiochemical synthesis of [11C]CPPC is described in detail, and a quality control summary of three validation productions is presented. The results indicate that the radiotracer product can be produced in good radiochemical yield (> 60 mCi (2.22 GBq) at end-of-synthesis (EOS)), at high specific activity (molar activity > 11,435 mCi/μmole (423 GBq/μmole) at EOS) and high chemical and radiochemical purity. The entire production conforms to current Good Manufacturing Practice (cGMP) requirements. The final product is formulated as a sterile, pyrogen-free solution suitable for human injection.

Original languageEnglish (US)
JournalJournal of Labelled Compounds and Radiopharmaceuticals
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Pyrogens
Microglia
Quality Control
Imaging techniques
Injections
Quality control
furan

Keywords

  • CPPC
  • CSF1R
  • PET
  • QC
  • synthesis

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Radiology Nuclear Medicine and imaging
  • Drug Discovery
  • Spectroscopy
  • Organic Chemistry

Cite this

@article{3f3d823470004aad8019c0b286f81af4,
title = "Radiosynthesis and validation of [5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl) furan-2-carboxamide] ([11C]CPPC), a PET radiotracer for imaging CSF1R, a microglia-specific marker",
abstract = "In this practitioner protocol, the radiochemical synthesis of [11C]CPPC is described in detail, and a quality control summary of three validation productions is presented. The results indicate that the radiotracer product can be produced in good radiochemical yield (> 60 mCi (2.22 GBq) at end-of-synthesis (EOS)), at high specific activity (molar activity > 11,435 mCi/μmole (423 GBq/μmole) at EOS) and high chemical and radiochemical purity. The entire production conforms to current Good Manufacturing Practice (cGMP) requirements. The final product is formulated as a sterile, pyrogen-free solution suitable for human injection.",
keywords = "CPPC, CSF1R, PET, QC, synthesis",
author = "Mathews, {William B.} and Yunkou Wu and Horti, {Andrew G.} and Ravi Naik and Hall, {Andrew W.} and Holt, {Daniel P.} and Dannals, {Robert F.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jlcr.3806",
language = "English (US)",
journal = "Journal of Labelled Compounds and Radiopharmaceuticals",
issn = "0362-4803",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Radiosynthesis and validation of [5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl) furan-2-carboxamide] ([11C]CPPC), a PET radiotracer for imaging CSF1R, a microglia-specific marker

AU - Mathews, William B.

AU - Wu, Yunkou

AU - Horti, Andrew G.

AU - Naik, Ravi

AU - Hall, Andrew W.

AU - Holt, Daniel P.

AU - Dannals, Robert F.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In this practitioner protocol, the radiochemical synthesis of [11C]CPPC is described in detail, and a quality control summary of three validation productions is presented. The results indicate that the radiotracer product can be produced in good radiochemical yield (> 60 mCi (2.22 GBq) at end-of-synthesis (EOS)), at high specific activity (molar activity > 11,435 mCi/μmole (423 GBq/μmole) at EOS) and high chemical and radiochemical purity. The entire production conforms to current Good Manufacturing Practice (cGMP) requirements. The final product is formulated as a sterile, pyrogen-free solution suitable for human injection.

AB - In this practitioner protocol, the radiochemical synthesis of [11C]CPPC is described in detail, and a quality control summary of three validation productions is presented. The results indicate that the radiotracer product can be produced in good radiochemical yield (> 60 mCi (2.22 GBq) at end-of-synthesis (EOS)), at high specific activity (molar activity > 11,435 mCi/μmole (423 GBq/μmole) at EOS) and high chemical and radiochemical purity. The entire production conforms to current Good Manufacturing Practice (cGMP) requirements. The final product is formulated as a sterile, pyrogen-free solution suitable for human injection.

KW - CPPC

KW - CSF1R

KW - PET

KW - QC

KW - synthesis

UR - http://www.scopus.com/inward/record.url?scp=85074829744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074829744&partnerID=8YFLogxK

U2 - 10.1002/jlcr.3806

DO - 10.1002/jlcr.3806

M3 - Article

C2 - 31524293

AN - SCOPUS:85074829744

JO - Journal of Labelled Compounds and Radiopharmaceuticals

JF - Journal of Labelled Compounds and Radiopharmaceuticals

SN - 0362-4803

ER -